Entrada Therapeutics, Inc.
TRDA
$8.36
$0.030.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.13M | -14.03M | 55.03M | 23.50M | -9.54M |
| Total Depreciation and Amortization | 992.00K | 937.00K | 910.00K | 934.00K | 736.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.19M | 1.65M | 2.36M | 1.70M | 1.84M |
| Change in Net Operating Assets | -35.92M | -12.82M | -18.47M | -51.65M | 2.95M |
| Cash from Operations | -31.61M | -24.27M | 39.83M | -25.52M | -4.01M |
| Capital Expenditure | -635.00K | -639.00K | -1.05M | -838.00K | -976.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.00M | -82.29M | -23.34M | 26.99M | 20.02M |
| Cash from Investing | 53.37M | -82.93M | -24.38M | 26.15M | 19.04M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.40M | -- | 101.37M | 206.00K | 690.00K |
| Repurchase of Common Stock | -- | -11.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.40M | -11.00K | 101.37M | 206.00K | 690.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.16M | -107.20M | 116.82M | 834.00K | 15.72M |